Novel swine model of transfusion-related acute lung injury

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2014-12, Vol.54 (12), p.3097-3107
• Main Authors: Okazaki, Hitoshi, Ishikawa, Osamu, Iijima, Takehiko, Kohira, Takahiro, Teranishi, Mai, Kawasaki, Shin, Saito, Akira, Mikami, Yu, Sugiura, Asuka, Hashimoto, Shiho, Shimada, Eiko, Uchikawa, Makoto, Matsuhashi, Mika, Tsuno, Nelson H., Tanaka, Minoru, Kiyokawa, Nobutaka, Fujimoto, Junichiro, Nagase, Takahide, Tadokoro, Kenji, Takahashi, Koki
• Format: Article
• Language: English
• Subjects: Acute Lung Injury - chemically induced; Acute Lung Injury - diagnostic imaging; Acute Lung Injury - physiopathology; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Animals; Antibodies, Monoclonal, Murine-Derived - immunology; Antibodies, Monoclonal, Murine-Derived - toxicity; Biological and medical sciences; Blood Transfusion; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Disease Models, Animal; Histocompatibility Antigens Class I - immunology; Humans; Lipopolysaccharides - toxicity; Lung - diagnostic imaging; Lung - physiopathology; Male; Medical sciences; Radiography; Respiratory Function Tests; Swine; Swine, Miniature; Transfusions. Complications. Transfusion reactions. Cell and gene therapy
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.12766

Background Transfusion‐related acute lung injury (TRALI) is a life‐threatening complication of blood transfusion. Antibodies against human leukocyte antigens in donors' plasma are the major causes of TRALI. Several animal models of TRALI have been developed, and the mechanism underlying TRALI development has been extensively investigated using rodent models. Although sheep models of nonimmune TRALI have been developed, large‐animal models of antibody‐mediated TRALI are not yet available. Study Design and Methods To develop a swine model of TRALI, male Clawn strain miniature pigs were used. A monoclonal antibody (MoAb) against swine leukocyte antigens (SLAs) Class I (4G8, 0.3 or 1.0 mg/kg body weight [BW]) and a control antibody (1.0 mg/kg BW) were injected into the peripheral vein after priming with or without 1 μg/kg BW lipopolysaccharide (LPS; n = 3 each). Lung injury was assessed using PaO2/FiO2 (P/F) ratio and by chest X‐ray imaging. Histopathologic analysis was also conducted. Results Lung injury could be induced by injecting 4G8 at an amount of 1.0 mg/kg BW, after LPS. The P/F ratio 90 minutes after the administration of 4G8 significantly decreased (p